AIM ImmunoTech Inc. (AIM)
2025-06-30 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Total revenues | 25 | 35 | 50 | |
| Research and development | 1,174 | 1,437 | 1,145 | |
| Production costs | 10 | 8 | 8 | |
| General and administrative | 1,487 | 3,079 | 2,591 | |
| Total costs and expenses | 2,671 | 4,524 | 3,744 | |
| Operating loss | -2,646 | -4,489 | -3,694 | |
| Interest expense and other finance costs | 149 | 202 | 179 | |
| (loss) on warrant issuance | - | - | - | |
| Gain (loss) on investments | -9 | 273 | -85 | |
| Interest and other income | 10 | 718 | 2,580 | |
| Gain loss on warrant issuance | - | - | -458 | |
| Net loss | -2,794 | -3,700 | -1,836 | |
| Basic loss per share | -3.68 | -0.06 | -0.03 | |
| Diluted loss per share | -3.68 | -0.06 | -0.03 | |
| Weighted average shares outstanding basic | 759,289 | 57,677,016 | 52,837,477 | |
| Weighted average shares outstanding diluted | 759,289 | 57,677,016 | 52,837,477 | |